Inventor · disambiguated record
Mark Wall
Also filed as: WALL MARK · WALL MARK J · WALL MARK JAMES
46 granted patents·8 pending applications·358 citations·filing 2003–2024
98Inventor score
Files withJANSSEN PHARMACEUTICA NV41ILLIG CARL R6DIMENSIONAL PHARM INC2JANSSEN SCIENCES IRELAND UNLIMITED CO2BRISTOL MYERS SQUIBB CO1
Top patents by PatentIndex Score
54 records- 0197US11767354B2Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptorsJANSSEN PHARMACEUTICA NV·Filed 2021·Granted Sep 26, 2023·3 cites·23 claims
- 0297US7645755B2Inhibitors of c-fms kinaseJANSSEN PHARMACEUTICA NV·Filed 2006·Granted Jan 12, 2010·45 cites·7 claims
- 0396US10428134B2Immunoglobulins and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Oct 1, 2019·7 cites·21 claims
- 0495US11591379B2Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptorsJANSSEN PHARMACEUTICA NV·Filed 2020·Granted Feb 28, 2023·3 cites·20 claims
- 0595US7973035B2Inhibitors of C-FMS kinaseJANSSEN PHARMACEUTICA NV·Filed 2008·Granted Jul 5, 2011·24 cites·12 claims
- 0695US7414050B2Inhibitors of c-fms kinaseJANSSEN PHARMACEUTICA NV·Filed 2007·Granted Aug 19, 2008·36 cites·16 claims
- 0794US10968265B2Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptorsJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Apr 6, 2021·4 cites·24 claims
- 0894US10787495B2Immunoglobulins and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2019·Granted Sep 29, 2020·3 cites·20 claims
- 0994US10640544B2Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptorsJANSSEN PHARMACEUTICA NV·Filed 2017·Granted May 5, 2020·4 cites·28 claims
- 1094US9453002B2Substituted imidazoles as N-type calcium channel blockersJANSSEN PHARMACEUTICA NV·Filed 2013·Granted Sep 27, 2016·18 cites·24 claims
- 1193US11401315B2Immunoglobulins and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2020·Granted Aug 2, 2022·2 cites·24 claims
- 1293US10858413B2Immunoglobulins and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Dec 8, 2020·3 cites·17 claims
- 1393US7795279B2Method of inhibiting FLT3 kinaseJANSSEN PHARMACEUTICA NV·Filed 2006·Granted Sep 14, 2010·30 cites·2 claims
- 1492US7662837B2Inhibitors of c-fms kinaseJANSSEN PHARMACEUTICA NV·Filed 2005·Granted Feb 16, 2010·26 cites·22 claims
- 1592US2025026803A1Immunoglobulins and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2024·Application pending·0 cites
- 1691US10968264B2Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptorsJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Apr 6, 2021·2 cites·31 claims
- 1791US10961293B2Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptorsJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Mar 30, 2021·2 cites·14 claims
- 1891US9434693B2Substituted pyrazoles as N-type calcium channel blockersJANSSEN PHARMACEUTICA NV·Filed 2013·Granted Sep 6, 2016·19 cites·20 claims
- 1989US2024018208A1Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptorsJANSSEN PHARMACEUTICA NV·Filed 2023·Application pending·0 cites
- 2088US8901314B2Substituted pyrazoles as N-type calcium channel blockersJANSSEN PHARMACEUTICA NV·Filed 2013·Granted Dec 2, 2014·12 cites·21 claims
- 2187US7138530B2Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditionsDIMENSIONAL PHARM INC·Filed 2003·Granted Nov 21, 2006·29 cites·48 claims
- 2286US11230526B1Cylcoalkenyl derivatives useful as agonists of the GPR120 and/or GPR40 receptorsJANSSEN PHARMACEUTICA NV·Filed 2019·Granted Jan 25, 2022·2 cites·25 claims
- 2386US2023365644A1Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptorsJANSSEN PHARMACEUTICA NV·Filed 2023·Application pending·0 cites
- 2485US8497376B2Inhibitors of c-fms kinaseILLIG CARL R·Filed 2008·Granted Jul 30, 2013·13 cites·16 claims
- 2584US8895584B2Inhibitors of c-fms kinaseJANSSEN PHARMACEUTICA NV·Filed 2014·Granted Nov 25, 2014·4 cites·16 claims
- 2684US8859602B2Inhibitors of c-fms kinaseILLIG CARL R·Filed 2007·Granted Oct 14, 2014·4 cites·11 claims
- 2784US8815867B2Inhibitors of c-fms kinaseILLIG CARL R·Filed 2007·Granted Aug 26, 2014·4 cites·9 claims
- 2883US7109354B2Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditionsDIMENSIONAL PHARM INC·Filed 2003·Granted Sep 19, 2006·17 cites·16 claims
- 2983US7030112B2Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disordersBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Apr 18, 2006·21 cites·2 claims
- 3080US8759347B2Inhibitors of C-FMS kinaseJANSSEN PHARMACEUTICA NV·Filed 2013·Granted Jun 24, 2014·3 cites·18 claims
- 3179US11732019B2Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptorsJANSSEN PHARMACEUTICA NV·Filed 2021·Granted Aug 22, 2023·0 cites·15 claims
- 3279US9296726B2Inhibitors of c-fms kinaseJANSSEN PHARMACEUTICA NV·Filed 2014·Granted Mar 29, 2016·2 cites·7 claims
- 3378US12134636B2Immunoglobulins and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2020·Granted Nov 5, 2024·0 cites·35 claims
- 3477US8481564B2Inhibitors of c-fms kinaseILLIG CARL R·Filed 2011·Granted Jul 9, 2013·2 cites·19 claims
- 3577US2024117000A1Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereofJANSSEN SCIENCES IRELAND UNLIMITED CO·Filed 2023·Application pending·0 cites
- 3676US9221797B2Inhibitors of c-fms kinaseJANSSEN PHARMACEUTICA NV·Filed 2014·Granted Dec 29, 2015·2 cites·18 claims
- 3776US7705042B2Class of arylamide compounds useful as inhibitors of c-fms kinaseJANSSEN PHARMACEUTICA NV·Filed 2005·Granted Apr 27, 2010·3 cites·11 claims
- 3874US7326788B2Quinolinone derivatives as inhibitors of c-fms kinaseJANSSEN PHARMACEUTICA NV·Filed 2004·Granted Feb 5, 2008·8 cites·6 claims
- 3973US9974775B2Substituted imidazoles as N-type calcium channel blockersJANSSEN PHARMACEUTICA NV·Filed 2016·Granted May 22, 2018·1 cites·16 claims
- 4068US9526731B2Method of inhibiting C-KIT kinaseJANSSEN PHARMACEUTICA NV·Filed 2014·Granted Dec 27, 2016·0 cites·1 claims
- 4168US8697716B2Method of inhibiting C-KIT kinaseILLIG CARL R·Filed 2007·Granted Apr 15, 2014·0 cites·2 claims
- 4267US9403804B2Inhibitors of c-fms kinaseJANSSEN PHARMACEUTICA NV·Filed 2014·Granted Aug 2, 2016·0 cites·11 claims
- 4367US9394289B2Inhibitors of c-fms kinaseJANSSEN PHARMACEUTICA NV·Filed 2014·Granted Jul 19, 2016·0 cites·9 claims
- 4465US11780900B2Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereofJANSSEN SCIENCES IRELAND UNLIMITED CO·Filed 2019·Granted Oct 10, 2023·0 cites·27 claims
- 4565US10653673B2Substituted imidazoles as N-type calcium channel blockersJANSSEN PHARMACEUTICA NV·Filed 2018·Granted May 19, 2020·0 cites·16 claims
- 4664US8933091B2Method of inhibiting C-KIT kinaseJANSSEN PHARMACEUTICA NV·Filed 2013·Granted Jan 13, 2015·0 cites·1 claims
- 4763US10875902B2Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2019·Granted Dec 29, 2020·0 cites·30 claims
- 4862US2023295157A13-(1h-imidazol-2-yl)-2,3,8,8a-tetrahydroindolizin-5(1h)-one derivatives useful as factor xia inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2021·Application pending·0 cites
- 4956US8674100B2Inhibitors of C-FMS kinaseILLIG CARL R·Filed 2007·Granted Mar 18, 2014·0 cites·24 claims
- 5051US9452996B2Inhibitors of c-fms kinaseJANSSEN PHARMACEUTICA NV·Filed 2015·Granted Sep 27, 2016·0 cites·16 claims
Showing the top 50 of 54 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Mark Wall files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →